Drugs that contain Tafluprost
1. Zioptan patents expiration
ZIOPTAN's oppositions filed in EPO
ZIOPTAN Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5886035 | THEA PHARMA | Difluoroprostaglandin derivatives and their use |
Dec, 2022
(1 year, 4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10864159 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) | |
| US9999593 | THEA PHARMA | Method and composition for treating ocular hypertension and glaucoma |
May, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of ZIOPTAN before it's drug patent expiration?
More Information on Dosage
ZIOPTAN family patents
